Bispectral Index (BIS) for Classification of Procalcitonin (PCT) Sepsis Grades in Critically Ill Patients With Sepsis

NCT03244293 · tracked via the Priya Life Science China tracker

Sponsor

Suez Canal University

Phase

Observational

Started

2014-01-01

Last updated

2026-04-23

Condition(s) studied

Sepsis, Severe

Investigational drug(s) / intervention(s)

no intervention

Study summary

To evaluate the discriminative power of BIS monitoring to classify the degree of mental state associated with the PCT graded sepsis cascade, and to assess its utility for monitoring the improvement or deterioration of sepsis.

Eligibility

Sex

ALL

Min age

—

Max age

—

Healthy volunteers

Inclusion Criteria: patients with sepsis * patients with sepsis Exclusion Criteria: * Patients who received drugs that would interfere with BIS monitoring

Primary outcome measure(s)

Bispectral Index (BIS)-Electroencephalography (EEG) derived parameter correlated to the severity of Sepsis as indicated by Procalcitonin (PCT) biomarker. — Time point 1= On CCU admission, Time point 2= day 3 of CCU admission, Time point 3= on release from CCU.
Bispectral Index (BIS)-Electroencephalography (EEG) derived parameter (scale from 0=brain dead to 100= normal EEG) will be monitored and correlated to the severity of Sepsis as indicated by daily measured Procalcitonin (PCT) biomarker (\<0.5 micg/L =no sepsis up to 100 micg/L =Septic shock)

Trial sites (1)

Facility	City	Region	Status
Dalian Medical University	Dalian	Dalian	Recruiting

More Suez Canal University trials in China

Bispectral-Electroencephalography (EEG) in First Time Hemodialysis Recruiting

Other trials for the same condition

Treatment Strategy of Human Gamma Globulin on the Therapy for Intensively Ill Children With Inflammatory Storm Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03244293 on ClinicalTrials.gov ↗ ← All trials in China